• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells.

作者信息

Sachinidis A, Ko Y, Weisser P, Meyer zu Brickwedde M K, Düsing R, Christian R, Wieczorek A J, Vetter H

机构信息

Medizinische Universitäts-Poliklinik, Bonn, Germany.

出版信息

J Hypertens. 1993 Feb;11(2):155-62. doi: 10.1097/00004872-199302000-00007.

DOI:10.1097/00004872-199302000-00007
PMID:8385175
Abstract

OBJECTIVE

EXP3174 is a metabolite of losartan (previous name DuP753), which is a non-peptide angiotensin II receptor antagonist.

DESIGN

The inhibitory potency of these two antagonists on the angiotensin II-induced responses in vascular smooth muscle cells (VSMC) was investigated.

METHODS

The effect of angiotensin II on cell growth was determined by [3H]-thymidine incorporation into cell DNA and by cellular protein measurements. Intracellular cytosolic Ca2+ concentration was measured by the fura-2 method. Inositolphosphates were determined by high-performance liquid chromatography after cell labelling with myo-[2-3H]-inositol. The early growth response gene-1 (Egr-1) messenger RNA (mRNA) expression was determined by the Northern blotting method. Binding and displacement studies of the antagonists were performed using [125I]-angiotensin II.

RESULTS

An apparent dissociation constant (Kd) of 5.9 nmol/l for [125I]-angiotensin II (maximal binding coefficient 69 fmol/10(6) cells) was found. The specific binding of [125I]-angiotensin II to VSMC was inhibited by losartan, EXP3174 and saralasin with a half-maximal inhibitory concentration (IC50) of 1.0 X 10(-8), 1.1 X 10(-9) and 1.8 X 10(-9) mol/l, respectively. EXP3174 and losartan abolished the angiotensin II-induced formation of inositolphosphates in VSMC. EXP3174 and losartan inhibited the angiotensin II-induced elevation of intracellular cytosolic Ca2+ concentration with an IC50 of 5 X 10(-9) and 5 X 10(-8) mol/l, respectively. EXP3174 was more effective than losartan in blocking the angiotensin II-induced increase in Egr-1 mRNA. EXP3174 and losartan inhibited the angiotensin II-induced cell protein synthesis with an IC50 of 3 X 10(-9) and 4 X 10(-8) mol/l, respectively.

CONCLUSIONS

These results indicate that EXP3174 is significantly more potent than losartan in blocking angiotensin II-induced cellular responses.

摘要

相似文献

1
EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells.
J Hypertens. 1993 Feb;11(2):155-62. doi: 10.1097/00004872-199302000-00007.
2
BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.BMS-180560,一种对血管紧张素II刺激反应具有不可克服性的抑制剂:与氯沙坦及EXP3174的比较。
Br J Pharmacol. 1994 Sep;113(1):179-89. doi: 10.1111/j.1476-5381.1994.tb16191.x.
3
In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.新型强效口服活性非肽类血管紧张素II受体拮抗剂UP 269-6对血管平滑肌细胞增殖的体外和体内作用
Br J Pharmacol. 1997 Feb;120(3):488-94. doi: 10.1038/sj.bjp.0700897.
4
Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).一种高效长效血管紧张素II受体拮抗剂2-乙氧基-1-[[2'-(1H-四氮唑-5-基)联苯-4-基]甲基]-1H-苯并咪唑-7-羧酸(CV-11974)及其前药(+/-)-1-(环己基氧羰基氧基)乙基2-乙氧基-1-[[2'-(1H-四氮唑-5-基)联苯-4-基]甲基]-1H-苯并咪唑-7-羧酸酯(TCV-116)的药理学特征
J Pharmacol Exp Ther. 1993 Jul;266(1):114-20.
5
Losartan inhibits the angiotensin II-induced stimulation of the phosphoinositide signalling system in vascular smooth muscle cells.
Eur J Pharmacol. 1992 Oct 1;227(2):215-9. doi: 10.1016/0922-4106(92)90130-n.
6
Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.通过受体结合和功能研究揭示的肽类和非肽类血管紧张素II拮抗剂的不同类型受体相互作用。
Mol Pharmacol. 1992 Jun;41(6):1081-8.
7
Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.非肽类血管紧张素II受体拮抗剂。XI. EXP3174的药理学:一种口服活性抗高血压药物DuP 753的活性代谢产物。
J Pharmacol Exp Ther. 1990 Oct;255(1):211-7.
8
Inhibitory effects of DuP 753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat.DuP 753和EXP3174对猫肺血管床中血管紧张素II反应的抑制作用。
J Appl Physiol (1985). 1992 Nov;73(5):2054-61. doi: 10.1152/jappl.1992.73.5.2054.
9
Angiotensin II-induced responses in vascular smooth muscle cells: inhibition by non-peptide receptor antagonists.
Eur J Pharmacol. 1995 Jul 14;280(3):285-92. doi: 10.1016/0014-2999(95)00206-z.
10
Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174.血管紧张素II受体拮抗剂氯沙坦钾(DuP 753/MK 954)及其药理活性代谢物EXP3174与人血浆蛋白的结合情况。
J Clin Pharmacol. 1995 May;35(5):515-20. doi: 10.1002/j.1552-4604.1995.tb04097.x.

引用本文的文献

1
Revealing Local Structure of Angiotensin Receptor-Neprilysin Inhibitor (S086) Drug Cocrystal by Linear and Nonlinear Infrared Spectroscopies.利用线性和非线性红外光谱揭示血管紧张素受体-中性肽链内切酶抑制剂(S086)药物共晶体的局部结构
ACS Omega. 2024 Dec 4;9(50):49683-49691. doi: 10.1021/acsomega.4c07887. eCollection 2024 Dec 17.
2
Changes in Pharmacokinetics and Pharmacodynamics of Losartan in Experimental Diseased Rats Treated with and .氯沙坦在接受[具体治疗方式1]和[具体治疗方式2]治疗的实验性患病大鼠体内的药代动力学和药效学变化。
Pharmaceuticals (Basel). 2022 Dec 26;16(1):33. doi: 10.3390/ph16010033.
3
Serum Concentrations of Losartan Metabolites Correlate With Improved Physical Function in a Pilot Study of Prefrail Older Adults.
洛沙坦代谢物的血清浓度与衰弱前期老年人的身体功能改善相关:一项初步研究
J Gerontol A Biol Sci Med Sci. 2022 Dec 29;77(12):2356-2366. doi: 10.1093/gerona/glac102.
4
Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling.使用基于生理的药代动力学模型预测细胞色素P450介导的水飞蓟宾A-氯沙坦药代动力学相互作用。
J Pharmacokinet Pharmacodyn. 2022 Jun;49(3):311-323. doi: 10.1007/s10928-022-09804-0. Epub 2022 Jan 21.
5
Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells.抗高血压药物治疗与人类 PSC 衍生的心肌细胞和原代内皮细胞对 SARS-CoV-2 感染的易感性。
Stem Cell Reports. 2021 Oct 12;16(10):2459-2472. doi: 10.1016/j.stemcr.2021.08.018. Epub 2021 Sep 1.
6
Nanoparticles Mimicking Viral Cell Recognition Strategies Are Superior Transporters into Mesangial Cells.模仿病毒细胞识别策略的纳米颗粒是进入系膜细胞的优质转运体。
Adv Sci (Weinh). 2020 Apr 22;7(11):1903204. doi: 10.1002/advs.201903204. eCollection 2020 Jun.
7
Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.氯沙坦挽救囊性纤维化相关模型中炎症相关的纤毛黏液功能障碍。
Am J Respir Crit Care Med. 2020 Feb 1;201(3):313-324. doi: 10.1164/rccm.201905-0990OC.
8
Simultaneous Determination and Pharmacokinetic Study of Losartan, Losartan Carboxylic Acid, Ramipril, Ramiprilat, and Hydrochlorothiazide in Rat Plasma by a Liquid Chromatography/Tandem Mass Spectrometry Method.液相色谱/串联质谱法同时测定大鼠血浆中氯沙坦、氯沙坦羧酸、雷米普利、雷米普利拉和氢氯噻嗪及其药代动力学研究
Sci Pharm. 2014 Nov 30;83(1):107-24. doi: 10.3797/scipharm.1410-15. Print 2015 Jan-Mar.
9
Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.韩国人群 CYP2C9 等位基因的频率及其对氯沙坦药代动力学的影响。
Acta Pharmacol Sin. 2011 Oct;32(10):1303-8. doi: 10.1038/aps.2011.100. Epub 2011 Aug 15.
10
Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.水飞蓟素对健康中国志愿者中氯沙坦及其活性代谢物E-3174药代动力学的影响。
Eur J Clin Pharmacol. 2009 Jun;65(6):585-91. doi: 10.1007/s00228-009-0624-9. Epub 2009 Feb 17.